Korro Bio, Inc. Debt Securities, Available-for-sale, Unrealized Gain
Korro Bio, Inc. (KRRO) reported Debt Securities, Available-for-sale, Unrealized Gain of $5.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain · last filed 2026-08-06
- Korro Bio, Inc. debt securities, available-for-sale, unrealized gain for the quarter ending 2026-06-30 was -$32.00K.
- Korro Bio, Inc. debt securities, available-for-sale, unrealized gain for the quarter ending 2026-03-31 was $37.00K, a 83.48% decline year-over-year.
- Korro Bio, Inc. debt securities, available-for-sale, unrealized gain for the quarter ending 2025-12-31 was -$4.00K.
- Korro Bio, Inc. debt securities, available-for-sale, unrealized gain for the quarter ending 2025-09-30 was $22.00K, a 96.21% decline year-over-year.
- Korro Bio, Inc. debt securities, available-for-sale, unrealized gain for fiscal 2024 was $282.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain 3 month | Debt Securities, Available-for-sale, Unrealized Gain 6 month | Debt Securities, Available-for-sale, Unrealized Gain 9 month | Debt Securities, Available-for-sale, Unrealized Gain 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$32.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $5.00K 10-Q · filed 2026-08-06 | $1.00K derived: sum of 3 quarters · filed 2026-08-06 | $23.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $37.00K 10-Q · filed 2026-05-07 | $33.00K derived: sum of 2 quarters · filed 2026-08-06 | $55.00K derived: sum of 3 quarters · filed 2026-08-06 | -$29.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$4.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-06 | $18.00K derived: sum of 2 quarters · filed 2026-08-06 | -$66.00K derived: sum of 3 quarters · filed 2026-08-06 | $158.00K 10-Q · filed 2026-08-06 |
| 2025-09-30 | $22.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$62.00K derived: sum of 2 quarters · filed 2025-11-12 | $162.00K 10-Q · filed 2025-11-12 | -$170.00K derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-06-30 | -$84.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $140.00K 10-Q · filed 2025-08-12 | -$192.00K derived: sum of 3 quarters · filed 2026-03-12 | $389.00K derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-03-31 | $224.00K 10-Q · filed 2025-05-07 | -$108.00K derived: sum of 2 quarters · filed 2026-03-12 | $473.00K derived: sum of 3 quarters · filed 2026-03-12 | |
| 2024-12-31 | -$332.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $249.00K derived: sum of 2 quarters · filed 2026-03-12 | $282.00K 10-K · filed 2026-03-12 | |
| 2024-09-30 | $581.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $614.00K 10-Q · filed 2024-11-12 | ||
| 2024-06-30 | $33.00K 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |